- Home
- NUKK vs CUE Comparison
NUKK vs CUE Comparison
Compare NUKK & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- CUE
- Stock Information
- Founded
- NUKK 2013
- CUE 2014
- Country
- NUKK United States
- CUE United States
- Employees
- NUKK N/A
- CUE N/A
- Industry
- NUKK Blank Checks
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- NUKK Finance
- CUE Health Care
- Exchange
- NUKK Nasdaq
- CUE Nasdaq
- Market Cap
- NUKK 52.1M
- CUE 52.8M
- IPO Year
- NUKK N/A
- CUE 2018
- Fundamental
- Price
- NUKK $8.05
- CUE $0.90
- Analyst Decision
- NUKK
- CUE Strong Buy
- Analyst Count
- NUKK 0
- CUE 3
- Target Price
- NUKK N/A
- CUE $3.00
- AVG Volume (30 Days)
- NUKK 237.7K
- CUE 644.9K
- Earning Date
- NUKK 09-10-2025
- CUE 08-13-2025
- Dividend Yield
- NUKK N/A
- CUE N/A
- EPS Growth
- NUKK N/A
- CUE N/A
- EPS
- NUKK N/A
- CUE N/A
- Revenue
- NUKK N/A
- CUE $7,991,000.00
- Revenue This Year
- NUKK N/A
- CUE N/A
- Revenue Next Year
- NUKK N/A
- CUE $23.84
- P/E Ratio
- NUKK N/A
- CUE N/A
- Revenue Growth
- NUKK N/A
- CUE 13.83
- 52 Week Low
- NUKK $1.30
- CUE $0.45
- 52 Week High
- NUKK $78.32
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- NUKK 33.66
- CUE 61.83
- Support Level
- NUKK $7.80
- CUE $0.71
- Resistance Level
- NUKK $8.43
- CUE $1.03
- Average True Range (ATR)
- NUKK 0.75
- CUE 0.08
- MACD
- NUKK -0.06
- CUE 0.01
- Stochastic Oscillator
- NUKK 16.41
- CUE 52.42
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.